Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa
- 603 Downloads
To evaluate the anatomical and functional outcomes of intravitreal dexamethasone implant in patients with macular edema (ME) secondary to retinitis pigmentosa (RP).
Three patients (four eyes), aged 24 to 46 years, presented with refractory ME secondary to RP. Intravitreal dexamethasone implant (Ozurdex) was administered to treat ME. The anatomical (central macular thickness [CMT]) and functional (best-corrected visual acuity [BCVA]) outcomes as well as adverse events were recorded.
All patients completed 6 months follow-up. After intravitreal Ozurdex all patients showed regression of ME. At baseline, mean CMT was 443 ± 185 μm (range 213–619 μm); ME improved to 234 ± 68 μm (range 142–307 μm) at 1 month, to 332 ± 177 μm (range 139–513 μm) at 3 msonth, and to 305 ± 124 μm (range 144–447 μm) at 6 months. Recurrent ME was recorded in 2 patients (both patients at 3 months from intravitreal dexamethasone implant). Retreatment with intravitreal Ozurdex was performed in two patients. Mean BCVA improved form 20/160 (range 20/50–20/200) (baseline) to 20/100 (range 20/40–20/125) at 1 month, to ∼20/125 (range 20/100–20/200) at 3 months, and to ∼ 20/125 (range 20/100–20/160) at 6 months. No serious ocular and systemic adverse events were observed during the study period.
Intravitreal dexamethasone implant provides anatomic and functional improvements and may represent a valuable treatment option for patients with ME secondary to RP.
KeywordsDexamethasone implant Macular edema Multifocal optical coherence tomography Ozurdex Retinitis pigmentosa
Conflict of interest
The authors have no proprietary interest in the materials used in this study.
- 7.Goldfien A (1995) Adrenocorticosteroids and adrenocortical antagonists. In: Katzung BG (ed) Basic and Clinical Pharmacology, 6th edn. Prentice Hall International, London, pp 592–607Google Scholar
- 8.Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM, Dexamethasone DDS Phase II Study Group (2007) Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 125:309–317PubMedCrossRefGoogle Scholar
- 9.Haller J, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, OZURDEX GENEVA Study Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–1146PubMedCrossRefGoogle Scholar
- 13.SCORE Study Research Group (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 6. Arch Ophthalmol 127:1115–1128CrossRefGoogle Scholar